Select a medication above to begin.
Cosentyx
secukinumab
Adult Dosing .
Dosage forms: INJ (Sensoready pen, SC): 150 mg per injection; INJ (UnoReady pen, SC): 300 mg per injection; INJ (pre-filled syringe, SC): 75 mg per 0.5 mL, 150 mg per mL, 300 mg per 2 mL; INJ (IV): various
psoriasis, mod-severe plaque
- [300 mg SC q4wk]
- Start: 300 mg SC qwk x5wk; Info: may consider 150 mg/dose in pts w/ less severe dz and wt <90 kg
psoriatic arthritis
- [SC route]
- Dose: 150 mg SC q4wk; Info: may load 150 mg SC qwk x5wk; consider incr. dose to 300 mg SC q4wk if active dz persists; use plaque psoriasis dosing for pts w/ coexisting dz
- [IV route]
- Dose: 1.75 mg/kg/dose IV q4wk; Max: 300 mg/maint. dose; Info: may load 6 mg/kg/dose IV x1
ankylosing spondylitis
- [SC route]
- Dose: 150 mg SC q4wk; Info: may load 150 mg SC qwk x5wk; consider incr. dose to 300 mg SC q4wk if active dz persists
- [IV route]
- Dose: 1.75 mg/kg/dose IV q4wk; Max: 300 mg/maint. dose; Info: may load 6 mg/kg/dose IV x1
axial spondyloarthritis, non-radiographic
- [SC route]
- Dose: 150 mg SC q4wk; Info: may load 150 mg SC qwk x5wk
- [IV route]
- Dose: 1.75 mg/kg/dose IV q4wk; Max: 300 mg/maint. dose; Info: may load 6 mg/kg/dose IV x1
hidradenitis suppurativa, moderate-severe
- [300 mg SC q4wk]
- Start: 300 mg SC qwk x5wk; Info: consider incr. dose to 300 mg SC q2wk if inadequate response
renal dosing
- [not defined]
- renal impairment: not defined
- HD/PD: not defined
hepatic dosing
- [not defined]
Peds Dosing .
- Dosage forms: INJ (Sensoready pen): 150 mg per injection; INJ (pre-filled syringe): 75 mg per 0.5 mL, 150 mg per mL
psoriasis, mod-severe plaque
- [6 yo and older, <50 kg]
- Dose: 75 mg SC q4wk; Start: 75 mg SC qwk x5wk
- [6 yo and older, >50 kg]
- Dose: 150 mg SC q4wk; Start: 150 mg SC qwk x5wk
psoriatic arthritis
- [2 yo and older, 15-49 kg]
- Dose: 75 mg SC q4wk; Start: 75 mg SC qwk x5wk
- [2 yo and older, >50 kg]
- Dose: 150 mg SC q4wk; Start: 150 mg SC qwk x5wk
enthesitis-related arthritis
- [4 yo and older, 15-49 kg]
- Dose: 75 mg SC q4wk; Start: 75 mg SC qwk x5wk
- [4 yo and older, >50 kg]
- Dose: 150 mg SC q4wk; Start: 150 mg SC qwk x5wk
renal dosing
- [not defined]
- renal impairment: not defined
- HD/PD: not defined
hepatic dosing
- [not defined]
Contraindications / Cautions .
- hypersensitivity to drug or ingredient
- infection, serious
- viral hepatitis, active
- TB infection, active
- caution: hypersensitivity to latex (prefilled syringe or pen form)
- caution: infection, chronic
- caution: infection, recurrent
- caution: infection risk
- caution: TB infection, latent
- caution: TB infection risk
- caution: inflammatory bowel dz
Drug Interactions .
Overview
secukinumab
IL-17 antagonist
- immunosuppressive effects
- caution advised w/ narrow therapeutic index drugs; chronic inflammatory conditions may alter metabolic enzyme formation; tx w/ immune modulators may reverse this effect, resulting in altered levels of concomitant drugs
Contraindicated
- adenovirus vaccine, live
- BCG live intravesical
- chikungunya vaccine, live
- cholera vaccine, live
- dengue vaccine, live
- influenza nasal vaccine, live
- measles/mumps/rubella vaccine, live
- rotavirus vaccine, live
- smallpox vaccine, live
- talimogene laherparepvec
- typhoid vaccine, live
- varicella vaccine, live
- yellow fever vaccine, live
Avoid/Use Alternative
- abrocitinib
- adalimumab
- anifrolumab
- cladribine oral
- deuruxolitinib
- etrasimod
- golimumab
- infliximab
- natalizumab
- pimecrolimus topical
- rabies vaccine
- ritlecitinib
- ruxolitinib topical
- upadacitinib
Monitor/Modify Tx
- anthrax vaccine
- carfilzomib
- chikungunya vaccine
- COVID-19 vaccine
- diphtheria/tetanus vaccine
- diphtheria/tetanus/pertussis vaccine
- ebola vaccine, live
- everolimus
- Haemophilus b vaccine
- hepatitis A vaccine
- hepatitis B vaccine
- human papillomavirus vaccine
- influenza H5N1 vaccine
- influenza vaccine
- Japanese encephalitis vaccine
- meningococcal vaccine
- pneumococcal vaccine
- poliovirus vaccine
- respiratory syncytial virus vaccine
- sipuleucel-T
- smallpox/mpox vaccine, live
- temsirolimus
- tick-borne encephalitis vaccine
- typhoid vaccine
Caution Advised
- abatacept
- abemaciclib
- acalabrutinib
- afamitresgene autoleucel
- aldesleukin
- alemtuzumab
- anakinra
- anti-thymocyte globulin
- atidarsagene autotemcel
- avacopan
- axicabtagene ciloleucel
- azacitidine
- azathioprine
- baricitinib
- basiliximab
- beclomethasone inhaled
- beclomethasone nasal
- belatacept
- belimumab
- belinostat
- bendamustine
- betamethasone
- bimekizumab
- blinatumomab
- bortezomib
- brentuximab vedotin
- brexucabtagene autoleucel
- brodalumab
- budesonide
- budesonide inhaled
- budesonide nasal
- budesonide rectal
- busulfan
- cabazitaxel
- canakinumab
- carboplatin
- carmustine
- certolizumab pegol
- chlorambucil
- ciltacabtagene autoleucel
- cisplatin
- cladribine injection
- clobetasol ophthalmic
- clofarabine
- copanlisib
- corticotropin
- cortisone
- crovalimab
- cyclophosphamide
- cyclosporine
- cytarabine
- dactinomycin
- danicopan
- daratumumab
- daunorubicin
- decitabine
- deflazacort
- delgocitinib topical
- deucravacitinib
- dexamethasone
- dexamethasone ophthalmic
- difluprednate ophthalmic
- dimethyl fumarate
- dinutuximab
- diroximel fumarate
- docetaxel
- doxorubicin
- dupilumab
- duvelisib
- eculizumab
- efgartigimod alfa
- elivaldogene autotemcel
- elotuzumab
- elranatamab
- emapalumab
- epcoritamab
- epirubicin
- eribulin
- etanercept
- etoposide
- fingolimod
- floxuridine
- fludarabine
- fludrocortisone
- flunisolide nasal
- fluocinolone intravitreal
- fluorometholone ophthalmic
- fluorouracil
- fluticasone furoate
- fluticasone propionate
- fruquintinib
- gemtuzumab ozogamicin
- glofitamab
- guselkumab
- hydrocortisone
- hydrocortisone ophthalmic
- hydroxyurea
- ibritumomab tiuxetan
- ibrutinib
- idarubicin
- idecabtagene vicleucel
- idelalisib
- ifosfamide
- inebilizumab
- inotuzumab ozogamicin
- iptacopan
- irinotecan
- isatuximab
- ixabepilone
- ixekizumab
- lebrikizumab
- leflunomide
- lenalidomide
- lifileucel
- linvoseltamab
- lisocabtagene maraleucel
- lomustine
- loncastuximab tesirine
- loteprednol ophthalmic
- lymphocyte immune globulin, anti-thymocyte globulin
- melphalan
- mercaptopurine
- methotrexate
- methylprednisolone
- mirikizumab
- mitoxantrone
- mogamulizumab
- momelotinib
- mometasone implant
- mometasone inhaled
- mometasone nasal
- monomethyl fumarate
- mosunetuzumab
- mycophenolate mofetil
- mycophenolic acid
- nadofaragene firadenovec intravesical
- nelarabine
- nipocalimab
- obecabtagene autoleucel
- obinutuzumab
- ocrelizumab
- ofatumumab
- oxaliplatin
- ozanimod
- paclitaxel
- panobinostat
- pegcetacoplan
- pentostatin
- pirtobrutinib
- polatuzumab vedotin
- pomalidomide
- ponatinib
- ponesimod
- pozelimab
- prednisolone
- prednisolone ophthalmic
- prednisone
- procarbazine
- quizartinib
- ravulizumab
- regorafenib
- rilonacept
- risankizumab
- rituximab
- romidepsin
- ropeginterferon alfa-2b
- rozanolixizumab
- ruxolitinib
- sarilumab
- satralizumab
- selinexor
- siltuximab
- siponimod
- sirolimus
- sirolimus albumin-bound
- spesolimab
- sulfasalazine
- sutimlimab
- tacrolimus
- tafasitamab
- talquetamab
- tarlatamab
- teclistamab
- temozolomide
- teplizumab
- teriflunomide
- thioguanine
- thiotepa
- tildrakizumab
- tisagenlecleucel
- tocilizumab
- tofacitinib
- topotecan
- tralokinumab
- triamcinolone
- tuberculin purified protein derivative
- ublituximab
- ustekinumab
- vamorolone
- vedolizumab
- venetoclax
- vilobelimab
- vinblastine
- vincristine
- vinorelbine
- voclosporin
- zanubrutinib
- zilucoplan
Adverse Reactions .
Serious Reactions
- hypersensitivity rxn
- anaphylaxis
- angioedema
- eczematous eruption, severe
- pyoderma gangrenosum
- inflammatory bowel dz
- infection, serious
- opportunistic infection
- HBV reactivation
- tuberculosis
- neutropenia
- sepsis (adult pts)
- toxic shock syndrome (peds pts)
Common Reactions
- infection
- nasopharyngitis
- neutropenia
- diarrhea
- URI
Safety/Monitoring .
Monitoring Parameters
TB test at baseline, then active TB s/sx during and after tx D/C
Pregnancy/Lactation .
Pregnancy
Clinical Summary
weigh risk/benefit during pregnancy; no human data available; risk of fetal harm not expected based on animal data at up to 30x MRHD
Lactation
Clinical Summary
weigh risk/benefit while breastfeeding; no human data available, though risk of infant harm not expected based on drug properties; no human data available to assess effects on milk production
Pharmacology .
Metabolism: unknown; CYP450: unknown
Excretion: unknown; Half-life: 22-31 days
Subclass: Interleukin-17 (IL-17) Antagonists ; Psoriasis, Systemic Agents ; Spondyloarthropathies
Mechanism of Action
selectively binds to and inhibits interleukin-17A cytokine, reducing inflammation and altering immune response (monoclonal antibody)
Formulary .
No Formulary Selected
Join Now to View Patient Handouts!
Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.
Current Members: Sign In.
Pill Pictures
Join Now to View Pill Pictures!
Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.
Current Members: Sign In.